Sylke Maas | Vice President of Investor Relations & Strategy |
Ugur Sahin | Chief Executive Officer & Co-Founder |
Ozlem Tureci | Chief Medical Officer & Co-Founder |
Jens Holstein | Chief Financial Officer |
Ryan Richardson | Chief Strategy Officer |
Sean Marett | Chief Business & Commercial Officer |
Cory Kasimov | JPMorgan |
Tazeen Ahmad | Bank of America |
Matthew Harrison | Morgan Stanley |
Chris Shibutani | Goldman Sachs |
Daina Graybosch | SVB Leerink |
Arlinda Lee | Canaccord |
Zhiqiang Shu | Berenberg |
Welcome to the BioNTech Fourth Quarter and Year-End Update Call. I would like to hand the call over to the Vice President of Investor Relations and Strategy, Sylke Maas. Please go ahead, Sylke.
Good morning and good afternoon, and thank you for joining us today to review BioNTech's fourth quarter and fiscal year 2021 operational progress and financial results. A few housekeeping items before we start.